Latest Advances in Lung Cancer Research

For many years, small cell lung cancer treatments stayed mostly the same. Chemotherapy was the main option, and immunotherapy added in 2018 only helped a little. But now, new therapies are bringing real hope to patients and their families.

New data shows elisrasib provides strong, lasting tumor responses for advanced lung cancer patients, including those who failed previous KRAS-targeted treatments.

Drs. Riely and Levy explain the necessity of reflex genomic testing in lung cancer to ensure personalized treatment and better patient outcomes.

Researchers from Yale University looked at more than 28,000 older adults with early-stage non-small cell lung cancer. They found that Black patients were 8 to 9 percentage points less likely than White patients to receive curative treatment.

New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.

Severe viral infections, such as COVID-19, can increase the risk of lung cancer through immune cell changes, though vaccination significantly reduces these long-term harmful effects.

Dr. Ross Camidge shares clinical insights and personal reflections on the evolution of lung cancer research and the vital importance of innovation in targeted therapies.

Lung cancer kills more people than breast, colon, and cervical cancers combined. Yet it is the cancer we screen for the least. A new study in the Journal of the American Medical Association shows that universal lung cancer screening could change this.

Mayo Clinic researchers found genetic and cellular clues, including missing a gene and “zombie cells”, that help explain why some lung tumors respond well to immunotherapy.

The FDA has fully approved the drug tarlatamab (Imdelltra) for small-cell lung cancer, after a trial showed it reduces death risk by ~40% compared with chemo.

A new NYT report shows that only a small fraction of people who qualify for lung-cancer screening get tested, leaving many early cancers undetected.

A Forbes article warns that few eligible Americans get lung cancer screening the and cancellation of a USPSTF meeting could delay important updates, worsening underuse.